| 2026 |
| 03/06 | 116 | 122 | 99 | 112 | 0% | 19,896,100 | 45億4314万 | +20.43% |
| 03/05 | 89 | 112 | 86 | 112 | +36.59% | 7,893,000 | 45億4314万 | +21.74% |
| 03/04 | 89 | 90 | 82 | 82 | -9.89% | 1,261,100 | 33億2623万 | -9.89% |
| 03/04 | （空売り報告）Nomura International plc 470,867株（1.16%）+0.49% |
| 03/03 | 95 | 95 | 90 | 91 | -3.19% | 792,900 | 36億9130万 | 0% |
| 03/03 | （空売り報告）Nomura International plc 272,367株（0.67%）+0.13% |
| 03/02 | 98 | 98 | 93 | 94 | -6% | 728,200 | 38億1299万 | +3.3% |
| 03/02 | （空売り報告）Nomura International plc 221,967株（0.54%）再IN |
| 02/27 | 89 | 100 | 88 | 100 | +13.64% | 1,525,000 | 40億5638万 | +9.89% |
| 02/27 | （空売り報告）Nomura International plc 144,567株（0.35%）-0.25%義務消失 |
| 02/26 | 88 | 90 | 87 | 88 | -1.12% | 307,300 | 35億6961万 | -3.3% |
| 02/26 | （空売り報告）Nomura International plc 247,367株（0.6%）+0.07% |
| 02/25 | 89 | 90 | 88 | 89 | 0% | 136,200 | 36億1017万 | -2.2% |
| 02/25 | （空売り報告）JPM Securities Japan Co Ltd. 203,000株（0.5%）再IN |
| 02/24 | 90 | 91 | 88 | 89 | -4.3% | 571,200 | 36億1017万 | -2.2% |
| 02/24 | （空売り報告）Nomura International plc 215,067株（0.53%）再IN |
| 02/20 | （IR情報）16:15 営業外収益(補助金収入)の計上に関するお知らせ |
| 02/20 | （IR情報）16:00 ファイナンスに関する説明資料 |
| 02/20 | （IR情報）16:00 当社開発品の進捗状況及びファイナンス実施に関するお知らせ |
| 02/20 | （IR情報）16:00 第三者割当による新株式及び第13回新株予約権(行使価額修正条項付)の発行に関するお知らせ |
| 02/20 | 94 | 94 | 92 | 93 | 0% | 179,900 | 37億7243万 | +2.2% |
| 02/19 | 95 | 95 | 92 | 93 | -2.11% | 342,000 | 37億7243万 | +2.2% |
| 02/18 | 95 | 96 | 93 | 95 | +1.06% | 307,200 | 38億5356万 | +5.56% |
| 02/18 | （空売り報告）Nomura International plc 192,667株（0.47%）-0.03%義務消失 |
| 02/17 | 96 | 96 | 93 | 94 | +1.08% | 258,200 | 38億1299万 | +4.44% |
| 02/17 | （空売り報告）Nomura International plc 205,367株（0.5%）再IN |
| 02/16 | 95 | 95 | 91 | 93 | +3.33% | 425,500 | 37億7243万 | +4.49% |
| 02/16 | （空売り報告）Nomura International plc 195,967株（0.48%）-0.11%義務消失 |
| 02/13 | 93 | 94 | 90 | 90 | -8.16% | 1,171,600 | 36億5074万 | +1.12% |
| 02/13 | （空売り報告）Nomura International plc 241,900株（0.59%）-0.16% |
| 02/12 | （IR情報）15:30 第13期定時株主総会の付議議案決定に関するお知らせ |
| 02/12 | （IR情報）15:30 2025年12月期決算短信〔日本基準〕(連結) |
| 02/12 | 101 | 102 | 96 | 98 | -2.97% | 2,082,300 | 39億7525万 | +10.11% |
| 02/12 | （空売り報告）UBS AG 185,100株（0.45%）-0.28%義務消失 |
| 02/12 | （空売り報告）Nomura International plc 305,000株（0.75%）再IN |
| 02/10 | 110 | 111 | 100 | 101 | -3.81% | 4,081,300 | 40億9694万 | +14.77% |
| 02/10 | （空売り報告）UBS AG 298,800株（0.73%）+0.19% |
| 02/09 | 100 | 111 | 97 | 105 | +15.38% | 10,363,800 | 42億5919万 | +20.69% |
| 02/09 | （空売り報告）Nomura International plc 0株（0%）-0.58%義務消失 |
| 02/06 | 88 | 106 | 87 | 91 | +8.33% | 13,039,100 | 36億9130万 | +5.81% |
| 02/06 | （空売り報告）UBS AG 220,500株（0.54%）再IN |
| 02/06 | （空売り報告）Nomura International plc 237,100株（0.58%）再IN |
| 02/05 | 84 | 86 | 83 | 84 | 0% | 127,000 | 34億735万 | -2.33% |
| 02/04 | 83 | 85 | 83 | 84 | 0% | 236,900 | 34億735万 | -2.33% |
| 02/03 | 85 | 85 | 83 | 84 | 0% | 315,700 | 34億735万 | -1.18% |
| 02/02 | 88 | 88 | 84 | 84 | -3.45% | 256,100 | 34億735万 | -1.18% |
| 01/30 | 88 | 88 | 87 | 87 | 0% | 325,100 | 35億2905万 | +2.35% |
| 01/29 | 88 | 88 | 87 | 87 | 0% | 98,500 | 35億2905万 | +3.57% |
| 01/28 | 91 | 91 | 87 | 87 | -3.33% | 278,400 | 35億2905万 | +3.57% |
| 01/27 | 91 | 91 | 89 | 90 | +1.12% | 231,200 | 36億5074万 | +8.43% |
| 01/26 | 92 | 92 | 88 | 89 | -5.32% | 837,600 | 36億1017万 | +7.23% |
| 01/23 | （IR情報）15:30 特別損失の計上及び業績予想の公表に関するお知らせ |
| 01/23 | 94 | 96 | 93 | 94 | +1.08% | 313,500 | 38億1299万 | +13.25% |
| 01/23 | （空売り報告）Barclays Capital Securities Ltd 165,300株（0.4%）-0.13%義務消失 |
| 01/22 | 98 | 98 | 92 | 93 | -3.13% | 1,024,100 | 37億7243万 | +13.41% |
| 01/21 | 91 | 111 | 91 | 96 | +9.09% | 6,060,800 | 38億9412万 | +17.07% |
| 01/21 | （空売り報告）Barclays Capital Securities Ltd 218,500株（0.53%）再IN |
| 01/20 | 89 | 91 | 88 | 88 | -1.12% | 259,400 | 35億6961万 | +8.64% |
| 01/19 | 89 | 90 | 87 | 89 | 0% | 281,500 | 36億1017万 | +9.88% |
| 01/16 | 86 | 89 | 85 | 89 | +4.71% | 308,200 | 36億1017万 | +9.88% |
| 01/15 | 82 | 86 | 82 | 85 | +2.41% | 308,200 | 34億4792万 | +4.94% |
| 01/14 | 81 | 83 | 81 | 83 | 0% | 163,600 | 33億6679万 | +2.47% |
| 01/13 | 82 | 83 | 81 | 83 | +1.22% | 55,400 | 33億6679万 | +2.47% |
| 01/09 | 82 | 83 | 81 | 82 | 0% | 121,200 | 33億2623万 | 0% |
| 01/08 | 83 | 83 | 82 | 82 | 0% | 31,600 | 33億2623万 | 0% |
| 01/07 | 82 | 83 | 82 | 82 | 0% | 88,800 | 33億2623万 | 0% |
| 01/06 | 81 | 82 | 80 | 82 | +1.23% | 129,700 | 33億2623万 | 0% |
| 01/05 | 82 | 82 | 80 | 81 | -1.22% | 244,800 | 32億8566万 | -1.22% |
| 2025 |
| 12/30 | 80 | 83 | 80 | 82 | +3.8% | 112,900 | 33億2623万 | -1.2% |
| 12/29 | 77 | 81 | 76 | 79 | +3.95% | 415,300 | 32億454万 | -4.82% |
| 12/26 | （IR情報）16:30 機能性ペプチド「SR-0379」の追加第3相臨床試験の被験者登録状況に関するお知らせ |
| 12/26 | 77 | 78 | 76 | 76 | -1.3% | 355,500 | 30億8284万 | -8.43% |
| 12/25 | 77 | 78 | 76 | 77 | 0% | 318,900 | 31億2341万 | -8.33% |
| 12/24 | 76 | 78 | 76 | 77 | +1.32% | 327,500 | 31億2341万 | -8.33% |
| 12/23 | 76 | 77 | 75 | 76 | 0% | 391,600 | 30億8284万 | -9.52% |
| 12/22 | 76 | 78 | 76 | 76 | 0% | 149,100 | 30億8284万 | -10.59% |
| 12/19 | 77 | 77 | 76 | 76 | -1.3% | 190,800 | 30億8284万 | -10.59% |
| 12/18 | 77 | 78 | 76 | 77 | 0% | 397,400 | 31億2341万 | -10.47% |
| 12/17 | 81 | 82 | 77 | 77 | -4.94% | 489,100 | 31億2341万 | -11.49% |
| 12/16 | 86 | 86 | 81 | 81 | -4.71% | 617,300 | 32億8566万 | -6.9% |
| 12/15 | 86 | 86 | 85 | 85 | -1.16% | 93,400 | 34億4792万 | -3.41% |
| 12/12 | 86 | 87 | 85 | 86 | 0% | 182,500 | 34億8848万 | -2.27% |
| 12/11 | 86 | 88 | 85 | 86 | 0% | 209,900 | 34億8848万 | -2.27% |
| 12/10 | 86 | 87 | 86 | 86 | 0% | 96,600 | 34億8848万 | -2.27% |
| 12/09 | 87 | 87 | 86 | 86 | -1.15% | 163,500 | 34億8848万 | -2.27% |
| 12/08 | 87 | 87 | 86 | 87 | +1.16% | 77,900 | 35億2905万 | -2.25% |
| 12/05 | 88 | 88 | 86 | 86 | -2.27% | 118,900 | 34億8848万 | -3.37% |
| 12/04 | 88 | 88 | 86 | 88 | +2.33% | 111,300 | 35億6961万 | -1.12% |
| 12/03 | 87 | 88 | 86 | 86 | -1.15% | 131,700 | 34億8848万 | -3.37% |
| 12/02 | 88 | 88 | 87 | 87 | -1.14% | 101,900 | 35億2905万 | -3.33% |
| 12/01 | 88 | 90 | 87 | 88 | 0% | 186,100 | 35億6961万 | -2.22% |
| 11/28 | 87 | 89 | 87 | 88 | 0% | 213,800 | 35億6961万 | -3.3% |
| 11/27 | 86 | 88 | 86 | 88 | +2.33% | 149,700 | 35億6961万 | -3.3% |
| 11/26 | 85 | 87 | 85 | 86 | 0% | 167,700 | 34億8848万 | -6.52% |
| 11/25 | 85 | 87 | 85 | 86 | +1.18% | 114,800 | 34億8848万 | -7.53% |
| 11/21 | 85 | 87 | 85 | 85 | -2.3% | 293,000 | 34億4792万 | -8.6% |
| 11/20 | 86 | 88 | 86 | 87 | +1.16% | 125,300 | 35億2905万 | -7.45% |
| 11/19 | 87 | 87 | 85 | 86 | -2.27% | 248,000 | 34億8848万 | -9.47% |
| 11/18 | 89 | 90 | 87 | 88 | -1.12% | 364,100 | 35億6961万 | -8.33% |
| 11/17 | 91 | 91 | 89 | 89 | -2.2% | 265,400 | 36億1017万 | -8.25% |
| 11/14 | （IR情報）15:30 2025年12月期第3四半期決算短信〔日本基準〕(連結) |
| 11/14 | 91 | 93 | 91 | 91 | 0% | 183,300 | 36億9130万 | -6.19% |
| 11/13 | 92 | 93 | 91 | 91 | -1.09% | 244,800 | 36億9130万 | -7.14% |
| 11/12 | 90 | 94 | 90 | 92 | +2.22% | 292,200 | 37億3186万 | -7.07% |
| 11/11 | 91 | 91 | 90 | 90 | -1.1% | 77,200 | 36億5074万 | -9.09% |
| 11/10 | 89 | 91 | 89 | 91 | +1.11% | 248,100 | 36億9130万 | -9% |
| 11/07 | 91 | 91 | 89 | 90 | -1.1% | 265,000 | 36億5074万 | -10.89% |
| 11/06 | 92 | 93 | 91 | 91 | -1.09% | 128,100 | 36億9130万 | -9.9% |
| 11/05 | 92 | 93 | 90 | 92 | 0% | 241,600 | 37億3186万 | -9.8% |
| 11/04 | 91 | 93 | 91 | 92 | 0% | 188,900 | 37億3186万 | -9.8% |
| 10/31 | 91 | 94 | 91 | 92 | 0% | 272,800 | 37億3186万 | -10.68% |
| 10/30 | 91 | 93 | 90 | 92 | +1.1% | 384,100 | 37億3186万 | -10.68% |
| 10/29 | 96 | 98 | 91 | 91 | -5.21% | 774,400 | 36億9130万 | -12.5% |
| 10/28 | 99 | 99 | 96 | 96 | -3.03% | 389,900 | 38億9412万 | -8.57% |
| 10/27 | 98 | 100 | 98 | 99 | +1.02% | 167,400 | 40億1581万 | -5.71% |
| 10/24 | 98 | 100 | 98 | 98 | -1.01% | 356,700 | 39億7525万 | -7.55% |
| 10/23 | （IR情報）12:15 アレルギーワクチンの第1相臨床試験における治験薬投与完了に関するお知らせ |
| 10/23 | 100 | 102 | 99 | 99 | -1% | 481,300 | 40億1581万 | -6.6% |
| 10/22 | 100 | 101 | 97 | 100 | -4.76% | 796,900 | 40億5638万 | -6.54% |
| 10/21 | （IR情報）16:00 抗体誘導ペプチド「FPP003」のオプション契約終了のお知らせ |
| 10/21 | 105 | 106 | 103 | 105 | +0.96% | 299,800 | 42億5919万 | -1.87% |
| 10/20 | 104 | 106 | 103 | 104 | 0% | 155,600 | 42億1863万 | -2.8% |
| 10/17 | 105 | 106 | 103 | 104 | -2.8% | 359,100 | 42億1863万 | -3.7% |
| 10/16 | 106 | 107 | 105 | 107 | +1.9% | 98,200 | 43億4032万 | -0.93% |
| 10/15 | 104 | 107 | 104 | 105 | +0.96% | 238,700 | 42億5919万 | -3.67% |
| 10/14 | 107 | 108 | 103 | 104 | -3.7% | 478,700 | 42億1863万 | -4.59% |
| 10/10 | 108 | 109 | 107 | 108 | -0.92% | 158,900 | 43億8089万 | -1.82% |
| 10/09 | 108 | 109 | 108 | 109 | 0% | 93,300 | 44億2145万 | -0.91% |
| 10/08 | 111 | 111 | 108 | 109 | -0.91% | 225,800 | 44億2145万 | -0.91% |
| 10/07 | 111 | 112 | 109 | 110 | +1.85% | 333,900 | 44億6201万 | -0.9% |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
